智通财经APP获悉，香港交易所(00388)证券产品发展主管罗博仁表示，生物科技为全球投资市场最备受 关注的主题之一。今年香港生物科技行业的增长动力依然稳固，并反映于相关股份及整体板块表现之 中。其中，恒生生物科技指数是市场广泛关注的基准之一。该指数于2025年录得64.5%的升幅，年初至 今(截至2026年2月24日)再上升10.7%。 恒生生物科技指数于2019年推出，追踪30家于香港上市、符合港股通资格的最大型生物科技公司。除专 注生物科技领域外，指数亦涵盖更广泛的医疗保健产业链。根据恒生指数有限公司资料，生物科技公司 约占指数权重的一半，制药企业则约占40%。为进一步提升分散度，指数亦纳入从事药品分销(约6%)以 及医疗器械与用品(约4%)的公司。 罗博仁表示，随着生物科技市场不断扩大，香港可供投资及风险管理的工具亦日趋多元。现时，香港交 易所的生物科技产品组合已涵盖股票、交易所买卖基金(ETF)、结构性产品及衍生工具。截至2026年2月 底，市场上共有10只追踪恒生生物科技指数的ETF(其中8只于内地上市，2只于香港上市)，总资产管理 规模达156亿港元。同时，与生物科技股份挂钩的结构性产品数目亦显 ...

Core Viewpoint - Hong Kong Stock Exchange (HKEX) reported its 2025 financial results, which met expectations, showing significant growth in revenue and net profit compared to the previous year [1] Revenue Breakdown - Total revenue for HKEX in 2025 reached HKD 29.16 billion, a year-on-year increase of 30% - Main revenue was HKD 27.11 billion, up 32% year-on-year, excluding investment income and charitable donations - Net profit for 2025 was HKD 17.75 billion, reflecting a 36% year-on-year increase - In Q4 2025, main revenue was HKD 6.67 billion, up 11% year-on-year but down 11% quarter-on-quarter; net profit was HKD 4.34 billion, up 15% year-on-year but down 12% quarter-on-quarter [1][2] Revenue by Fee Type - Revenue by fee type for 2025 was as follows: - Trading fees: HKD 10.33 billion (38%) - Clearing and settlement fees: HKD 7.04 billion (26%) - Investment income: HKD 5.11 billion (19%) - Listing fees: HKD 1.79 billion (7%) - Custody and agency services fees: HKD 1.50 billion (6%) - Market data fees: HKD 1.17 billion (4%) - Year-on-year growth rates for various fees included: - Trading fees: +44% - Clearing and settlement fees: +49% - Listing fees: +21% - Custody and agency services fees: +31% - Market data fees: +8% - Investment income: +4% [2] Market Activity - Average Daily Turnover (ADT) for Hong Kong stocks in 2025 was HKD 249.8 billion, a 90% year-on-year increase - Q4 2025 ADT was HKD 229.8 billion, up 23% year-on-year but down 20% quarter-on-quarter - Southbound ADT for 2025 was HKD 121.1 billion, up 151% year-on-year, contributing 24.2% to total ADT - Northbound ADT for 2025 was RMB 212.4 billion, up 42% year-on-year [3] IPO Market - HKEX maintained its position as the global leader in IPO fundraising, with 119 new listings in 2025 and total IPO proceeds of HKD 286.9 billion, a 226% year-on-year increase - Over two-thirds of IPO proceeds came from new economy companies - As of January 26, 2026, there were over 400 IPO applications in process, including more than 50 applications under specific listing rules [3] Investment Income - Investment income for HKEX in 2025 was HKD 5.11 billion, a 4% year-on-year increase - Q4 2025 investment income was HKD 1.22 billion, up 2% year-on-year and quarter-on-quarter - The contribution of investment income to net profit was 28% [3] Profit Forecast and Rating - The company has adjusted its profit forecasts downward for 2026 and 2027, while introducing a forecast for 2028 - Expected net profits for 2026, 2027, and 2028 are HKD 17.59 billion, HKD 18.36 billion, and HKD 19.51 billion, respectively - The current PE ratio for 2026 is projected at 29.7x, close to historical lows, indicating potential investment value [3]

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its stock performance relative to the market [6][4]. Core Insights - The company reported a total revenue of HKD 29.16 billion for 2025, reflecting a year-on-year growth of 30%. The main revenue component was HKD 27.11 billion, with a net profit of HKD 17.75 billion, marking a 36% increase year-on-year [4][6]. - The report highlights a significant increase in fee-related income, with various fee categories showing double-digit growth. Trading fees grew by 44%, and settlement and clearing fees increased by 49% [6][4]. - The report notes a decline in margin investment yields, with the weighted yield for margin financing at 1.31%, down from 1.51% in 2024 [6][4]. Financial Data and Earnings Forecast - The financial projections for the company are as follows: - Revenue for 2026 is estimated at HKD 28.32 billion, a decrease of 3% from 2025, with a net profit forecast of HKD 17.59 billion, a slight decline of 1% [5][7]. - The earnings per share (EPS) for 2026 is projected to be HKD 13.9, with a return on equity (ROE) of 29.8% [5][7]. - The report provides a detailed breakdown of revenue sources, with trading fees contributing 38%, settlement and clearing fees 26%, and investment income 19% [6][7]. Market Position and Trends - The Hong Kong stock market maintained its position as the global leader in IPO fundraising, with 119 new listings in 2025, raising HKD 286.9 billion, a 226% increase year-on-year [6][4]. - The report emphasizes the strong performance of the company's derivatives segment, with an average daily volume (ADV) of 166,000 contracts, a 7% increase year-on-year [6][4]. - The report also notes that the company is well-positioned to benefit from the ongoing deepening of connectivity between Hong Kong and mainland China, which is expected to enhance its market value [6][4].

上 市 公 司 非银金融 2026 年 02 月 26 日 香港交易所 (00388) ——费类收入同比双位数高增，保证金投资量增价减 一年内股价与基准指数对比走势： -15% 5% 25% 45% HSCEI 香港交易所 资料来源：Bloomberg 报告原因：有业绩公布需要点评 买入（维持） | 市场数据： | 2026 年 02 月 25 日 | | --- | --- | | 收盘价（港币） | 412.20 | | 恒生中国企业指数 | 9034.75 | | 52 周最高/最低（港币） | 466.00/283.20 | | H 股市值（亿港币） | 5,226.02 | | 流通 H 股（百万股） | 1,267.84 | | 汇率（港币/人民币） | 0.8861 | 相关研究 《香港交易所（00388）深度：成长性可验 证，有望迎来重估》 2025/07/24 证券分析师 罗钻辉 A0230523090004 luozh@swsresearch.com 金黎丹 A0230525060004 jinld@swsresearch.com 联系人 金黎丹 A0230525060004 jinld@ ...

Market Overview - As of January 2026, the total market capitalization of the Hong Kong securities market reached HKD 50.8 trillion, a 44% increase from HKD 35.4 trillion in the same period last year [1] - In January 2026, the Hong Kong Stock Exchange welcomed 13 new listings, a 63% increase compared to 8 new listings in January 2025 [1] - The total fundraising amount in January 2026 was HKD 531 billion, up 318% from HKD 127 billion in January 2025 [1] Trading Activity - The average daily trading amount in January 2026 was HKD 2,723 billion, an 89% increase from HKD 1,438 billion in January 2025 [1] - The average daily trading amount for derivative warrants was HKD 78 billion, a 77% increase from HKD 44 billion in January 2025 [1] - The average daily trading amount for bull and bear certificates was HKD 142 billion, a 100% increase from HKD 71 billion in January 2025 [1] - The average daily trading amount for exchange-traded funds was HKD 359 billion, a 69% increase from HKD 212 billion in January 2025 [1] - The average daily trading amount for leveraged and inverse products was HKD 31 billion, a 19% increase from HKD 26 billion in January 2025 [1] Derivatives Market - The average daily trading volume for futures and options in January 2026 was 1,706,438 contracts, an 18% increase from 1,452,108 contracts in January 2025 [2] - The average daily trading volume for stock options was 900,960 contracts, a 19% increase from 759,565 contracts in January 2025 [2] Historical Records - On January 29, 2026, the trading volume of the Hang Seng Tech Index options reached a historical high of 39,229 contracts [3] - On January 28, 2026, the trading volume of the Hang Seng Biotech Index futures reached a historical high of 1,013 contracts [4]

香港金融市场在2025年表现非常活跃，并在新股市场及二级市场创下多项交易纪录新高，彰显香港作为亚洲领先国际 金融中心的地位。 新一代创新企业纷纷来港上市并藉着香港的平台继续扩展；与此同时，来自全球各地的投资者也藉着香港交易所市场 上多元化的产品组合捕捉机遇并进行风险管理。香港交易所的年度市场数据显示，现货证券及期货期权市场的集资活 动和产品生态圈都较前一年更丰富、多元和活跃。以下亮点分别回顾香港市场2025年的表现及介绍2026年的展望。 香港新股市场重回全球第一 2025年香港共迎来119家新上市企业，首次公开招股集资总额达到2,858亿港元，其中三家更跻身2025年全球十大新股 之列。新能源及人工智能等创新领域的发行人引领着强劲的创新科技市场浪潮，2025年香港新上市公司当中，新经济 公司占比超过三分之二。根据Dealogic的数据，在香港交易所上市的公司全年通过后续发行筹集了660亿美元，较2024 年的279亿美元升136%，充分印证了香港资本市场的活力和深度。 衍生产品成交创新高， 巩固亚洲风险管理中心地位 现货市场成交金额创新高 2025 年香港现货市场日均成交额按年增长 89.5%，达到 2,4 ...

Group 1 - Hong Kong's capital market is projected to regain the top position in global IPO fundraising in 2025, with a total of $37.4 billion, surpassing the total of the previous three years and marking the highest level since 2021 [1] - The strong performance is driven by eight IPOs exceeding $1 billion and a diverse range of new economy companies, indicating a shift towards a more diversified market structure [1] - Newly listed stocks have shown positive performance, with an average first-day increase of 23.8% and a cumulative first-month increase of 30.7%, particularly in the biotechnology and healthcare sectors [1] Group 2 - The A+H share listing has emerged as a significant highlight, with 19 A-share companies completing H-share listings in 2025, raising $17.7 billion and enhancing the international investor base for these companies [2] - By the end of 2025, 96 A-share companies had submitted applications for listing in Hong Kong, with over 70 expressing intent to list, suggesting that A+H listings may continue to be a focus in 2026 [2] - The derivatives market is expanding alongside new stock listings, with the introduction of stock options for companies like CATL, providing investors with immediate risk management tools [2]

Core Insights - The Hong Kong IPO market is expected to maintain its strong momentum from 2025 into 2026, driven by market diversification, internationalization, and an active secondary market [1][13]. Group 1: IPO Market Recovery - In 2025, Hong Kong's capital market saw a full recovery with 119 companies listed, a 68% increase from 2024, and IPO fundraising exceeding 285.8 billion HKD, marking a 225% surge [3][15]. - The biotechnology sector was particularly notable, with a growth rate exceeding 60% in 2025, attracting significant international investor interest in Chinese tech companies [6][18]. Group 2: Internationalization and Market Activity - The active secondary market supported IPOs, with the average daily trading volume in 2025 increasing by over 90% compared to 2024, maintaining around 250 billion HKD [9][21]. - International companies from regions such as Thailand, Singapore, Kazakhstan, and the Middle East have begun listing in Hong Kong, with 12 companies raising approximately 400 million USD in early 2026 [10][22]. Group 3: Product Innovation and Connectivity - The Hong Kong Stock Exchange (HKEX) is focusing on product innovation to enhance market vitality, including the introduction of the Tech 100 Index and biotechnology index futures [11][23]. - Future expansions of the "connectivity" mechanism may include integrating Real Estate Investment Trusts (REITs) and promoting "Renminbi counter" inclusion in the Hong Kong Stock Connect [11][23]. Group 4: Future Outlook - The HKEX anticipates that diversification and internationalization will be key themes for the Hong Kong stock market in 2026, with growth expected across various sectors including technology, biotechnology, and international companies [12][24].

2024年9月24日以来，资本市场进入回暖上涨阶段，恒生生物科技指数累计涨幅达78.6%，跑赢港股通 创新药指数，展现出高弹性与高夏普比率的特征。 | | 恒生生物科技 | 恒生港股通创新药 | 港股通创新药 | 恒生医疗保健 | 港股通医疗主题 | | --- | --- | --- | --- | --- | --- | | 年化收益率(%) | 59. 42 | 57.50 | 59.07 | 51. 55 | 53. 41 | | 年化波动率(%) | 41.03 | 42.66 | 43. 50 | 39. 35 | 41.58 | | 最大回撤(%) | -27.55 | -27.35 | -27.08 | -28.51 | -30. 54 | | 夏普比率 | 1.45 | 1. 35 | 1.36 | 1.31 | 1.28 | | 累计收益(%) | 78. 64 | 75.97 | 78. 14 | 67.74 | 70. 29 | | 2025年以来收益(%) | 67. 50 | 66. 61 | 69.44 | 59.83 | 51. 12 | 数据来源：Wind，2025年以来数据 ...

Core Insights - The Hong Kong Stock Exchange (HKEX) has successfully raised approximately HKD 285.7 billion through 117 IPOs in 2025, marking a significant recovery in IPO fundraising, surpassing the HKD 200 billion threshold for the first time in four years and leading globally in IPO fundraising [1] Group 1: Listing System Optimization - HKEX has implemented effective measures in listing systems, market infrastructure, and product ecosystem since 2025 to enhance listing services and market liquidity [2] - The introduction of the "Tech Company Fast Track" in May 2025 facilitates the listing process for tech and biotech companies, allowing them to submit applications confidentially [2] - Reforms in August 2025 improved the pricing and public holding requirements for IPOs, providing greater flexibility and certainty for issuers while balancing the needs of local and international investors [2] Group 2: Attracting International Companies - HKEX is actively attracting international companies to list in Hong Kong by expanding the list of recognized exchanges, making it easier for overseas firms to pursue secondary listings [3] - Several Southeast Asian companies from Thailand, Indonesia, and Singapore have either listed or submitted applications in Hong Kong since 2025 [3] Group 3: Market Liquidity and Activity Enhancement - HKEX has implemented reforms to boost secondary market activity and liquidity, including lowering the minimum tick size in August 2025 to reduce trading costs and enhance price discovery [4] - The introduction of the Hang Seng Biotech Index futures in November 2025 provides risk management tools for investors, complementing existing biotech-related products [4] - The launch of the Tech 100 Index tracks 100 well-known large and mid-cap companies across six major technology sectors, enriching the product ecosystem [4] Group 4: Continued Growth in the IPO Market - The IPO market in Hong Kong continues to show strong growth, with over 300 listing applications currently under review [5] - HKEX plans to enhance its attractiveness to global investors and issuers in 2026 by developing traditional stock business alongside commodities and fixed income sectors [5] - Deloitte China predicts around 160 new listings in Hong Kong in 2026, with a minimum fundraising target of HKD 300 billion, including approximately seven large IPOs exceeding HKD 10 billion [6]